Meningococcemia cost-effectiveness of therapy: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
m (Changes made per Mahshid's request) |
||
| (5 intermediate revisions by one other user not shown) | |||
| Line 3: | Line 3: | ||
{{CMG}} ; {{AE}} {{Ammu}} | {{CMG}} ; {{AE}} {{Ammu}} | ||
==Overview== | ==Overview== | ||
Cost effective analysis study has indicated that a 2-dose series at ages 11 years and 16 years has a similar cost-effectiveness compared with moving the single dose to age 15 years or maintaining the single dose at 11 years. | |||
==Cost-effective Analysis== | ==Cost-effective Analysis== | ||
*As part of the evaluation of the adolescent vaccination program, a cost-effectiveness analysis was performed to compare the cost-effectiveness of the following three vaccination strategies: <ref name=CDC>{{cite web | title = The Centers for Disease Control and Prevention(CDC)| url =http://www.cdc.gov/mmwr/preview/mmwrhtml/rr6202a1.htm}}</ref> | *As part of the evaluation of the adolescent vaccination program, a cost-effectiveness analysis was performed to compare the cost-effectiveness of the following three vaccination strategies: <ref name=CDC>{{cite web | title = The Centers for Disease Control and Prevention(CDC)| url =http://www.cdc.gov/mmwr/preview/mmwrhtml/rr6202a1.htm}}</ref> | ||
| Line 9: | Line 11: | ||
:* A single dose at age 15 years | :* A single dose at age 15 years | ||
:* A dose at age 11 years with a booster dose at age 16 years. The economic costs and benefits of these meningococcal vaccination strategies in adolescents were assessed from a societal perspective <ref name="pmid11934772">{{cite journal| author=Trotter CL, Edmunds WJ| title=Modelling cost effectiveness of meningococcal serogroup C conjugate vaccination campaign in England and Wales. | journal=BMJ | year= 2002 | volume= 324 | issue= 7341 | pages= 809 | pmid=11934772 | doi= | pmc=PMC100788 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11934772 }} </ref><ref name="pmid15867028">{{cite journal| author=Shepard CW, Ortega-Sanchez IR, Scott RD, Rosenstein NE, ABCs Team| title=Cost-effectiveness of conjugate meningococcal vaccination strategies in the United States. | journal=Pediatrics | year= 2005 | volume= 115 | issue= 5 | pages= 1220-32 | pmid=15867028 | doi=10.1542/peds.2004-2514 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15867028 }} </ref>. | :* A dose at age 11 years with a booster dose at age 16 years. The economic costs and benefits of these meningococcal vaccination strategies in adolescents were assessed from a societal perspective <ref name="pmid11934772">{{cite journal| author=Trotter CL, Edmunds WJ| title=Modelling cost effectiveness of meningococcal serogroup C conjugate vaccination campaign in England and Wales. | journal=BMJ | year= 2002 | volume= 324 | issue= 7341 | pages= 809 | pmid=11934772 | doi= | pmc=PMC100788 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11934772 }} </ref><ref name="pmid15867028">{{cite journal| author=Shepard CW, Ortega-Sanchez IR, Scott RD, Rosenstein NE, ABCs Team| title=Cost-effectiveness of conjugate meningococcal vaccination strategies in the United States. | journal=Pediatrics | year= 2005 | volume= 115 | issue= 5 | pages= 1220-32 | pmid=15867028 | doi=10.1542/peds.2004-2514 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15867028 }} </ref>. | ||
[[File:Cost effective Analysis.png|thumb|center|700px| <SMALL><SMALL> ''[(http://www.cdc.gov/meningococcal/)]''<ref name="CDC">{{Cite web | title =The Centers for Disease Control and Prevention(CDC) | url = http://www.cdc.gov/meningococcal/}}</ref></SMALL></SMALL>]] | |||
*A multivariable analysis was performed with a Monte Carlo simulation in which multiple parameters were varied simultaneously over specified probability distributions. | |||
*These parameters included disease incidence (46%–120% of the 10-year average), case-fatality ratio (34%–131% of the 10-year average), rates of long-term sequelae, acute meningococcal disease costs (i.e., inpatient care, parents' work loss, public health response, and premature mortality costs), lifetime direct and indirect costs of meningococcal disease sequelae (i.e., long-term special education and reduced productivity), and cost of vaccine and vaccine administration (range: $64–$114). | |||
*Vaccination coverage (37%–90%) and initial vaccine efficacy (39%–99%) also were varied for evaluation purposes. | |||
*The vaccine was assumed to be 93% effective in the first year, and then waning immunity was modeled as a linear decline over the next 9 years unless a booster dose was administered. | |||
*The vaccine effectiveness of the second dose was assumed to be higher with a slower rate of waning immunity. | |||
*The results of the cost-effectiveness analysis indicate that a 2-dose series at ages 11 years and 16 years has a similar cost-effectiveness compared with moving the single dose to age 15 years or maintaining the single dose at 11 years. However, the number of cases and deaths prevented is substantially higher with the 2-dose strategy | |||
==References== | ==References== | ||
| Line 17: | Line 26: | ||
[[Category:Emergency medicine]] | [[Category:Emergency medicine]] | ||
[[Category:Hematology]] | [[Category:Hematology]] | ||
[[Category:Neurology]] | [[Category:Neurology]] | ||
[[Category:Pediatrics]] | [[Category:Pediatrics]] | ||
Latest revision as of 18:03, 18 September 2017
|
Meningococcemia Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Meningococcemia cost-effectiveness of therapy On the Web |
|
American Roentgen Ray Society Images of Meningococcemia cost-effectiveness of therapy |
|
Risk calculators and risk factors for Meningococcemia cost-effectiveness of therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]
Overview
Cost effective analysis study has indicated that a 2-dose series at ages 11 years and 16 years has a similar cost-effectiveness compared with moving the single dose to age 15 years or maintaining the single dose at 11 years.
Cost-effective Analysis
- As part of the evaluation of the adolescent vaccination program, a cost-effectiveness analysis was performed to compare the cost-effectiveness of the following three vaccination strategies: [1]
- A multivariable analysis was performed with a Monte Carlo simulation in which multiple parameters were varied simultaneously over specified probability distributions.
- These parameters included disease incidence (46%–120% of the 10-year average), case-fatality ratio (34%–131% of the 10-year average), rates of long-term sequelae, acute meningococcal disease costs (i.e., inpatient care, parents' work loss, public health response, and premature mortality costs), lifetime direct and indirect costs of meningococcal disease sequelae (i.e., long-term special education and reduced productivity), and cost of vaccine and vaccine administration (range: $64–$114).
- Vaccination coverage (37%–90%) and initial vaccine efficacy (39%–99%) also were varied for evaluation purposes.
- The vaccine was assumed to be 93% effective in the first year, and then waning immunity was modeled as a linear decline over the next 9 years unless a booster dose was administered.
- The vaccine effectiveness of the second dose was assumed to be higher with a slower rate of waning immunity.
- The results of the cost-effectiveness analysis indicate that a 2-dose series at ages 11 years and 16 years has a similar cost-effectiveness compared with moving the single dose to age 15 years or maintaining the single dose at 11 years. However, the number of cases and deaths prevented is substantially higher with the 2-dose strategy
References
- ↑ 1.0 1.1 "The Centers for Disease Control and Prevention(CDC)".
- ↑ Trotter CL, Edmunds WJ (2002). "Modelling cost effectiveness of meningococcal serogroup C conjugate vaccination campaign in England and Wales". BMJ. 324 (7341): 809. PMC 100788. PMID 11934772.
- ↑ Shepard CW, Ortega-Sanchez IR, Scott RD, Rosenstein NE, ABCs Team (2005). "Cost-effectiveness of conjugate meningococcal vaccination strategies in the United States". Pediatrics. 115 (5): 1220–32. doi:10.1542/peds.2004-2514. PMID 15867028.